Skip to content
MedsAcross

Molecule

Alclometasone dipropionate

Corticosteroid
Available on request
Presentations
2
Brands
0
Manufacturers
0
Available from stock
0

Alclometasone dipropionate is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is available as ointment and cream for topical use. MedsAcross supplies Alclometasone dipropionate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Corticosteroid, Corticosteroid Hormone Receptor Agonists
US FDA first approval
14 December 1982
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Topical
Dosage forms
Ointment, Cream
Identifiers
UNII S56PQL4N1VRxCUI 17268CAS 66734-13-2Q27114198

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Alclometasone Dipropionate Ointment USP, 0.05% is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Alclometasone dipropionate ointment may be used in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established. Since the safety and efficacy of alclometasone dipropionate ointment has not been established in pediatric patients below 1 year of age, their use in this age-group is not recommended.

Source: US FDA prescribing information

Dosing overview

Apply a thin film of Alclometasone Dipropionate Ointment USP, 0.05% to the affected skin areas two or three times daily, massage gently until the medication disappears. Alclometasone dipropionate ointment may be used in pediatric patients 1 year of age or older. Safety and effectiveness of alclometasone dipropionate ointment in pediatric patients for more than 3 weeks of use have not been established. Use in pediatric patients under 1 year of age is not recommended. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Alclometasone dipropionate ointment should not be used with occlusive dressings unless directed by a physician.

Source: US FDA prescribing information

Contraindications

Alclometasone Dipropionate Ointment USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components in this preparation.

Source: US FDA prescribing information

Warnings and precautions

General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. The effects of alclometasone dipropionate ointment on the HPA axis have been evaluated.

Source: US FDA prescribing information

Side effects

The following local adverse reactions have been reported with alclometasone dipropionate ointment in approximately 1% of patients: itching, burning, and erythema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

2 presentations of Alclometasone dipropionate, sorted by availability.

MedicineManufacturerRegisterAvailability
Alclometasone dipropionate 0.05% ointmentTopicalGeneric name—US FDAAvailable on request
Alclometasone dipropionate 0.05% creamTopicalGeneric name—US FDAAvailable on request

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 14 December 1982Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Alclometasone dipropionate available for export from India?

Yes, on request. MedsAcross lists 2 presentations of Alclometasone dipropionate and sources them for licensed hospitals, importers and physicians against valid import documents.

Is Alclometasone dipropionate approved by the US FDA?

Yes. The US FDA first approved Alclometasone dipropionate on 14 December 1982, according to Drugs@FDA.

Does Alclometasone dipropionate need cold chain shipping?

No listed presentation of Alclometasone dipropionate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

References

  1. Alclometasone Dipropionate prescribing information (Sun Pharmaceutical Industries). U.S. National Library of Medicine, DailyMed. Retrieved 13 August 2025

Request Alclometasone dipropionate for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.